Elite in Stroke

Bruce C. Campbell

245 Burgundy Street, 
Heidelberg, VIC, AU 
Elite in Stroke
245 Burgundy Street, 
Heidelberg, VIC, AU 
OverviewLocationsClinical Research

Overview

Bruce Campbell practices in Heidelberg, Australia. Mr. Campbell is rated as an Elite expert by MediFind in the treatment of Stroke. His top areas of expertise are Stroke, Carotid Artery Disease, Transient Ischemic Attack (TIA), Thrombectomy, and Patent Foramen Ovale Repair.

His clinical research consists of co-authoring 407 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 347 articles and participated in 4 clinical trials in the study of Stroke.

Gender
Male

Locations

245 Burgundy Street, Heidelberg, VIC 3084, Australia
Other Locations
Grattan St, Parkville, VIC 3052, Australia
Grattan Street, Parkville, VIC 3050, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Multicentre, Prospective Randomized Open Label, Blinded-endpoint (PROBE) Controlled Trial of Thrombolysis With Low Dose Tenecteplase (TNK-tPA) Versus Standard of Care in Minor Ischemic Stroke With Proven Acute Symptomatic Occlusion
Multicentre, Prospective Randomized Open Label, Blinded-endpoint (PROBE) Controlled Trial of Thrombolysis With Low Dose Tenecteplase (TNK-tPA) Versus Standard of Care in Minor Ischemic Stroke With Proven Acute Symptomatic Occlusion
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drugs: Tenecteplase, Antiplatelet Monotherapy
Study Phase: Phase 3
SELECT2: A Randomized Controlled Trial to Optimize Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke
SELECT2: A Randomized Controlled Trial to Optimize Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke
Enrollment Status: Completed
Publish Date: November 21, 2024
Intervention Type: Other, Device
Study Phase: Not Applicable
EXTEND-IA TNK: Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra-Arterial Using Intravenous Tenecteplase Part 2
EXTEND-IA TNK: Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra-Arterial Using Intravenous Tenecteplase Part 2
Enrollment Status: Completed
Publish Date: March 04, 2020
Intervention Type: Drug
Study Phase: Phase 2
Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra-Arterial Using Intravenous Tenecteplase
Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra-Arterial Using Intravenous Tenecteplase
Enrollment Status: Completed
Publish Date: March 30, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

407 Total Publications

Alteplase 4.5 to 24 Hours After Acute Ischemic Stroke-Reply.
Alteplase 4.5 to 24 Hours After Acute Ischemic Stroke-Reply.
Journal: JAMA
Published: December 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Campbell's expertise for a condition
ConditionClose
    View All 22 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile